Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease

Дата публикации: 28-07-2026 00:00:00

This randomized clinical trial examines the safety and efficacy of low-dose rivaroxaban in the treatment of patients with advanced chronic kidney disease at high risk for cardiovascular events.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	SGLT2 Inhibitors for Prevention of AKI	0	16.3	30-07-2026
2	Seven-Year Valve Durability With TAVR	0	11.52	01-08-2026
3	Remdesivir and Graft Loss in Kidney Transplant Recipients With Symptomatic COVID-19	0	8.68	28-07-2026
4	Clopidogrel Plus Aspirin vs Aspirin Alone in Patients With Acute Mild to Moderate Stroke	0	5.05	01-05-2024
5	Spectrum of Aldosteronism and Cardiovascular Outcomes	0	6.27	01-04-2026
6	Efficacy and Safety of Brolucizumab for Diabetic Macular Edema	0	7.97	01-12-2023
7	Cardiovascular Risk Reclassification With the 2026 Dyslipidemia Guideline	0	11.38	18-08-2026
8	Cognitive Outcomes After Catheter Ablation for Atrial Fibrillation	0	8.06	31-07-2026
9	Vutrisiran Treatment and Cardiac and Amyloid Changes on MRI	0	5.2	12-08-2026
10	Novo Nordisk Provides Update on the ZEUS Phase 3 Trial of Ziltivekimab in People with ASCVD, CKD and Inflammation	0	12.26	31-07-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 8.74. Источник: archderm.jamanetwork.com.